I am a cancer researcher trained in cell biology, immunology and molecular oncology. I made major contributions to the discoveries that defects in cell death can cause cancer, autoimmune disease and impair the response of cancers to chemotherapy. My current work aims to reach a detailed understanding of the molecular mechanisms of programmed cell death and to exploit this knowledge to develop novel therapeutics for cancer and autoimmune diseases that can directly activate this process.
Targeting Mechanisms That Promote Cancer Cell Survival: Genetic And Chemical Approaches To Unravel The Molecular Mechanisms That Drive Tumour Formation, Develop Novel Molecular And Chemical Probes, And Discover New Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$751,854.00
Summary
One in three of us are likely to die from cancers. Groundbreaking research, including those made by Prof Huang, has revealed some of the reasons why cancers arise. An attractive way to transform the poor outcomes for cancer patients is to develop better medicines based on findings made by the basic researchers. Prof Huang leads a team at WEHI, including chemists, focused on developing better drugs that exploit knowledge garnered through such basic research in order to improve cancer treatment.
Regulation Of Cell Death, Cell Survival And Ubiquitination In Normal Physiology And Disease
Funder
National Health and Medical Research Council
Funding Amount
$823,008.00
Summary
I am a cellular and molecular biologist with extensive training in a number of biomedical research areas. For over 20 years I have used my training and skills to understand the normal functioning of the body and what molecular and cellular changes underlie various diseases. This fellowship will allow me to continue the groundbreaking work we have been doing to explore the function of several proteins in diseases such as cancer, hypertension, lung inflammation and anaemia.
MicroRNA Pathway Control Of Immune Cell Development
Funder
National Health and Medical Research Council
Funding Amount
$631,370.00
Summary
The immune system is comprised of many different cell types, each with a specialised function. Many are short-lived and must be continually replenished throughout life. Abnormalities in this process underlie many human diseases, including immunodeficiency, autoimmunity and cancer. My laboratory seeks to understand the molecular pathways that control development of immune cells and to identify the defects that lead to disease.
DNA damage response pathways play important roles in preventing the onset of cancer and regulating the clinical response to chemotherapeutics, and some of the relevant proteins have additional functions during normal development. This fellowship will study new a human protein with key roles in the formation of the lung, and its roles in preventing devastating consequences of normal oxidative damage to DNA, as well as additional fundamental mechanisms involved in preventing genome mutations.
Regulation And Mechanisms Of Cell Cycling, Cell Senescence And Cell Death
Funder
National Health and Medical Research Council
Funding Amount
$876,005.00
Summary
Most of our cells are not dividing, but persist in a stable arrested state, yet little is known of the molecular mechanisms that regulate and maintain permanent arrest, or that go wrong when cells start proliferating and turn into cancers. This proposal addresses an area of fundamental, basic biology, that has been largely overlooked. A better understanding of the molecules that regulate cell stability might provide new drug targets so that tumour cell proliferation can be stopped.
Determining recurrence risk in breast cancer is crucial, as more than half of all recurrences occur after 5 years. However, optimal management of breast cancer is hampered by the challenges in finding rational preventative and predictive targets. Our vision is to find targets responsible for progenitor cell expansion, as candidates for prevention, and to find markers of relapse, to predict early versus late responders to therapy.
Prevention Of Pancreatic Beta Cell Destruction In Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$621,458.00
Summary
Associate Professor Helen Thomas is a molecular and cell biologist with a particular interest in pancreatic islet biology, studying the mechanisms of pancreatic beta-cell destruction in diabetes. The aim of this work is to develop strategies to protect these cells. Such protection will improve our ability to preserve beta-cell mass in type 1 and type 2 diabetes, and after islet transplantation.
Learning The Mechanisms Of Programmed Cell Death And Tumour Suppression To Develop Novel Cancer Therapies
Funder
National Health and Medical Research Council
Funding Amount
$863,910.00
Summary
Our bodies prevent the development of cancer through tumour suppressive processes, which also affect the outcome of cancer therapy. Programmed cell death (apoptosis) is one such process, and defects in apoptosis promote cancer development and impair the response of tumour cells to anti-cancer therapies. My laboratory uses molecular biology and cell biology approaches to investigate the mechanisms of cell death and tumour suppression, partnering with pharma to develop novel cancer therapies.
Manipulating Oncogenic-signalling Pathways In The Genesis And Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$601,484.00
Summary
Melanoma is a major Australian health problem. It is the third most common cancer in men and women and has a disproportionately heavy impact on productive years of life. The use of small molecule inhibitors is the most promising strategy for treating melanoma. In this project, we will examine the mechanisms of resistance to this class of drugs and define new drug targets by examining the molecular-circuitry is damaged in melanomas. This work will greatly accelerate the development of new therapi ....Melanoma is a major Australian health problem. It is the third most common cancer in men and women and has a disproportionately heavy impact on productive years of life. The use of small molecule inhibitors is the most promising strategy for treating melanoma. In this project, we will examine the mechanisms of resistance to this class of drugs and define new drug targets by examining the molecular-circuitry is damaged in melanomas. This work will greatly accelerate the development of new therapies.Read moreRead less